Last reviewed · How we verify
DPI-386 Nasal Gel
DPI-386 Nasal Gel is a Small molecule drug developed by Repurposed Therapeutics, Inc.. It is currently in Phase 3 development. Also known as: scopolamine, Transderm Scop®.
DPI-386 is a repurposed therapeutic delivered as a nasal gel formulation, designed to provide local or systemic therapeutic effects through intranasal administration.
At a glance
| Generic name | DPI-386 Nasal Gel |
|---|---|
| Also known as | scopolamine, Transderm Scop® |
| Sponsor | Repurposed Therapeutics, Inc. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
DPI-386 represents a drug repurposing strategy by Repurposed Therapeutics, reformulated as a nasal gel to improve bioavailability and patient convenience through the intranasal route. The nasal delivery pathway allows for direct absorption across the nasal mucosa, potentially bypassing first-pass hepatic metabolism and enabling lower systemic doses. The specific molecular mechanism depends on the active pharmaceutical ingredient being repurposed, which is not publicly detailed in available sources.
Approved indications
Common side effects
Key clinical trials
- Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance (PHASE2)
- Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance (PHASE2)
- Prevention and Treatment of Nausea Associated With Motion Sickness in Senior Subjects (PHASE3)
- Efficacy and Safety of DPI-386 Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion (PHASE3)
- Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion (PHASE3)
- Nasal Gel Under Military Operational Conditions for the Prevention of Nausea Associated With Motion Sickness (PHASE3)
- DPI 386 Nasal Gel for the Prevention of Nausea Associated With Motion Sickness (PHASE2, PHASE3)
- The Prevention and Treatment of Nausea Associated With Motion Sickness (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DPI-386 Nasal Gel CI brief — competitive landscape report
- DPI-386 Nasal Gel updates RSS · CI watch RSS
- Repurposed Therapeutics, Inc. portfolio CI
Frequently asked questions about DPI-386 Nasal Gel
What is DPI-386 Nasal Gel?
How does DPI-386 Nasal Gel work?
Who makes DPI-386 Nasal Gel?
Is DPI-386 Nasal Gel also known as anything else?
What development phase is DPI-386 Nasal Gel in?
Related
- Manufacturer: Repurposed Therapeutics, Inc. — full pipeline
- Also known as: scopolamine, Transderm Scop®
- Compare: DPI-386 Nasal Gel vs similar drugs
- Pricing: DPI-386 Nasal Gel cost, discount & access